BioNTech (NasdaqGS:BNTX) is in focus after management moved to exit certain German manufacturing sites, a shift that could ...

Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...

BioNTech’s share price has declined about 57.5% over the past five years, and with the stock closing at US$92.98 and ...

BERLIN, July 3 (Reuters) - BioNTech has held confidential talks with potential buyers about German sites that the COVID‑19 ...

BioNTech (BNTX) stock is in focus as the company holds talks with prospective bidders regarding plans to shutter ...

Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines ...

BioNTech SE has agreed to acquire British artificial intelligence (AI) startup InstaDeep for up to 562 million pounds ($682 ...

BERLIN (Reuters) -BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German ...

The COVID-19 pandemic was a rare event. Governments took it upon themselves to inoculate their populations by buying millions of doses of vaccines from companies such as BioNTech and Pfizer. The ...

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million. It ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of ...

BERLIN, July 3 (Reuters) - BioNTech has held confidential talks with potential buyers about the German sites that the ...